The Use of Procalcitonin (PCT) for Diagnosis of Sepsis in Burn Patients: A Meta-Analysis

Luís Cabral¹,²*, Vera Afreixo³, Luís Almeida⁴, José Artur Paiva⁴,⁵

¹ Department of Plastic Surgery and Burns Unit, Coimbra Hospital and University Centre (CHUC), Coimbra, Portugal, ² Autonomous Section of Health Sciences (SACS), University of Aveiro, Aveiro, Portugal, ³ CIDMA —Center for Research and Development in Mathematics and Applications; iBiMED—Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ⁴ Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal, ⁵ Department of Emergency and Intensive Care Medicine, Centro Hospitalar São João, Porto, Portugal

* jlacabral@gmail.com

Abstract

The continuous development of resuscitation techniques and intensive care reduced the mortality rate induced by the initial shock in burn patients and, currently, infections (especially sepsis) are the main causes of mortality of these patients. The misuse of antimicrobial agents is strongly related to antimicrobial and adverse patient outcomes, development of microbial resistance and increased healthcare-related costs. To overcome these risks, antimicrobial stewardship is mandatory and biomarkers are useful to avoid unnecessary medical prescription, to monitor antimicrobial therapy and to support the decision of its stop. Among a large array of laboratory tests, procalcitonin (PCT) emerged as the leading biomarker to accurately and time-effectively indicate the presence of systemic infection. In the presence of systemic infection, PCT blood levels undergo a sudden and dramatic increase, following the course of the infection, and quickly subside after the control of the septic process. This work is a meta-analysis on PCT performance as a biomarker for sepsis. This meta–analysis showed that overall pooled area under the curve (AUC) is 0.83 (95% CI = 0.76 to 0.90); the estimated cut-off is 1.47 ng/mL. The overall sepsis effect in PCT levels is significant and strong (Cohen’s d is 2.1 and 95% CI = 1.1 to 3.2). This meta–analysis showed PCT may be considered as a biomarker with a strong diagnostic ability to discriminate between the septic from the non-septic burn patients. Thus, this work encourages the determination of PCT levels in clinical practice for the management of these patients, in order to timely identify the susceptibility to sepsis and to initiate the antimicrobial therapy, improving the patients’ outcomes.

Introduction

Comparing to other critical patients, severe burn victims have a higher susceptibility to develop infectious complications leading to sepsis, which is the major cause of mortality in these patients, and may result from intrinsic and extrinsic factors [1,2]. The former may include loss of skin barrier, humoral and cellular immunodepression, presence of necrotic...
tissue, bacterial translocation and diminution of airway clearance when inhalation injuries are 
associated. The later comprise the use of invasive devices (intravascular catheters, endotracheal 
tubes, indwelling bladder catheters, etc.), immobilization and exposition to nosocomial flora 
[2,3].

Clinical signs and laboratorial findings commonly used to diagnose the presence of infec-
tion are not specific and are difficult to interpret due to the magnitude of the systemic inflam-
atory response unfettered by large burns, which mimics a septic episode. The consensus 
international definition of sepsis, formulated by the American College of Chest Physicians and 
by the Society of Critical Care Medicine (ACCP/SCCM) [4,5], was subjected to a revision for 
burn patients by the American Burn Association [6] (see Annex 1) [S1 File]. This revision 
implied the modification of some cut-offs and the concomitant documentation of microbio-
logical identification. Nevertheless, currently, the definite identification of microbiological 
agents still takes two to four days [7]. As stated by Kumar [8] and confirmed by many other 
studies, the prompt administration of an adequate antimicrobial therapy is the most important 
isolated factor for the survival of the septic patient and any hourly delay is associated with an 
increase in mortality.

Burn surgeons are therefore urged to start antimicrobial therapy at the first evidence of 
infection, but it requires a strong clinical expertise, attending to the lack of a time-effective 
microbiological confirmation. An adequate therapy reduces the microbial counting, which 
enables the body systems to control and stop the infectious episode. This is, however, a 
dynamic process: there are resistant microorganisms that may survive, even when treated with 
the most effective bactericidal agents. Some microorganisms develop mutations capable of 
overlapping the antibiotic action, giving rise to microbial resistance (i.e. making the drug inef-
fective), and thus they may spread to other cells and tissues, being responsible for a systemic 
infection. To reduce the possibilities of development of microbial resistance is crucial to avoid 
unnecessary administration of antimicrobial therapy. On the other hand, the prompt begin-
nning of the therapy, with the right dose of an effective drug at the first evidence of infection is 
equally important, so are the selection of the right drug targeting the microbiological agent 
and to limit the duration of treatment to the strictly necessary, preventing antibiotic resistance 
and selective pressure on the microorganisms [9]. This strategy has additional advantages, 
including the reduction of medication side effects, healthcare-related costs and, in most cases, 
the length of hospitalization (providing that the surgical treatment of the burns is achieved).

The use of biomarkers has been recommended to help clinicians to timely decide when to 
start antimicrobial therapy, to monitor its evolution and to advise its early suspension. From 
the currently available biomarkers, procalcitonin (PCT) has shown the greatest accuracy to 
indicate the presence of systemic infections within an acceptable timing, in a great range of 
clinical scenarios [10–12].

This work is an extended and updated version of the paper published by Ren et al. [13] [S2 
File], including the overall estimation and discussion of several other effect sizes in PCT levels 
and incorporating four other studies. Its aim is to summarize literature data (through meta-
analysis) about the use of PCT for the early detection of sepsis in burn patients, and to discuss 
the proposed PCT cut-offs for the diagnosis of sepsis.

**Material and Methods**

**Data source**

PubMed, Scopus and Web of Science databases were used. The combined search term used for 
this search was: [procalcitonin OR PCT) AND (sepsis OR septic) AND burn]. The search was 
performed up to 1st December 2015.
Data extraction, evaluation and synthesis

Only articles written in English focusing on burn patients and on the evaluation of PCT role on the diagnosis and monitoring of septic episodes were considered. Titles and abstracts of records retrieved by the search were screened to determine their relevance. Relevant studies were reviewed in full text, in order to determine their relevance for the meta-analysis. After reading titles and eliminating duplicates (LC and VA), 96 abstracts were independently assessed by three authors (LC, VA and LA), and, from these, 14 references were subjected to detailed analysis and included in the sample, by consensus or majority decision.

Inclusion and exclusion criteria

A study was considered eligible for inclusion in the meta-analysis if it provided area under the curve (AUC) on serum PCT for diagnosis of sepsis or the serum PCT levels by sepsis and non-sepsis groups in burn patients.

Statistical analysis

Two techniques were used to calculate the pooled effect estimates: the inverse variance assuming a fixed-effects model, and the DerSimonian-Laird method assuming a random-effects model. Homogeneity among studies was evaluated using the Cochran’s Q statistic and the $I^2$ statistic (the values of 0.25, 0.50, and 0.75 indicating low, moderate, and high degrees of heterogeneity). Publication bias was evaluated using the funnel plot and the Egger regression asymmetry test. To investigate potentially different effects according to the study, subgroup analyses were performed. Sensitivity analysis to show the impact of each study or subgroup studies on the results was also held.

MetaDiSc 1.4 (XI Cochrane Colloquium, Barcelona, Spain) was used to calculate the summary receiver operating characteristics (SROC) and the pooled AUC [14]. MetaXL 2.0 (EpiGear International Pty Ltd, Wilston, Queensland, Australia) was used to calculate the pooled Cohen’s d effect sizes (difference of PCT levels between sepsis and non-sepsis groups, the pooled AUC and pooled mean effects [15].

The weight average of all PCT cut-off for sepsis diagnosis proposed in the studies under analysis was also measured.

Results

The removal of duplicates from the 160 articles that were initially identified through search in PubMed, Scopus and Web of Science resulted in 96 individual articles (Fig 1). The great majority did not fulfill the eligibility criteria. After exclusion of ineligible papers, 14 articles, comprising a temporal range from 1997 to 2015, were found to meet the inclusion criteria and were selected for review.

Plasma PCT concentrations had been measured using different methods, such as PCT-Q immunochromatography (Brahms Diagnostica, Berlin, Germany) [15,16], PCT-Lumi immunoluminometric (Brahms Diagnostica, Berlin, Germany) [16–21], electrochemical luminescence immunoassay (ECLIA) (Brahms Diagnostica, Berlin, Germany) [22–24], and immunoassay sandwich and final fluorescence technique (VIDAS, bioMérieux, Marcy L’Etoile, France) [25].

Two studies were pediatric [20,26], one mixed [18] and the remaining studies included only adult patients [15–19,21,23–25,27–29].

Studies also differ in the PCT cut-off defined for sepsis suspicion. Reported cut-off values include 0.5 ng/mL [23], 0.534 ng/mL [16], 0.69 ng/mL [22], 1.5 ng/mL [19,27], 1.7 ng/mL...
[23], increment of 1.5 ng/mL in two consecutive days [18], 2 ng/mL [25,29]; 3 ng/mL [17], and 5 ng/mL [20]. Using the different cut-offs for sepsis diagnosis proposed in each study (Table 1), the weight average of all PCT cut-offs for sepsis was computed and the resulting cut-off was 1.59 ng/mL. Fig 2 shows a bubble plot of cut-off for PCT in sepsis diagnosis for 12 studies organized by year. The two older studies showed the highest cut-offs values; if these two studies are excluded, the estimated value is 1.47 ng/mL.

Data uniformization

Data uniformization is required for the meta-analysis of Cohen’s d effect size. In the study of Sachse et al. [18], PCT values were reported as the median by different post-burn time intervals (6 distinct intervals) for septic and non-septic groups; the average and the standard deviation of PCT values were deduced assuming the normal behavior of PCT values (mean = \( \frac{\sum \text{median}_i}{6} \); std = \( \sqrt{\text{std}_{\text{median}}} \).

In Neely et al. [20] and Lavrentieva et al. [27] (both in sepsis and non-sepsis groups PCT standard deviation by each group was obtained using the inter-quartile distance and assuming the normal behavior of PCT values (interquartile range = 1.35\( \sigma \)). In Cakir Madenci et al. paper [22], it was calculated using the quantiles 2.5% and 97.5% and the normality assumption (\( x_{0.975} - x_{0.025} = 3.92\sigma \)).
In Bargues et al. [16], log values were transformed and combined in order to obtain the PCT average and standard deviation, and the subgroup values are combined to obtain the pooled standard deviation and the weight average. Lavrentieva et al. [19] combined subgroup values to obtain the pooled standard deviation and the weight average of PCT for non-sepsis groups.

As Barati et al. [15], Bognar et al. [29] and Mokline et al. [21] did not present AUC standard error, the estimates for standard error were computed using the Hanley and McNeil procedure [30]. Paratz et al. [24] reported the PCT discriminative power as not significant with AUC = 0.38 (95% Confidence Interval (95% CI) 0.29 to 0.46). However, if the classifier was negated on every instance, the true positive (TP) classifications become false negative and the false positive become true negative (TN), and we obtain AUC = 0.62 and, for the cut-off chosen by the authors (1.4 ng/mL), the corresponding sensitivity is 80 and the specificity is 36.

In Lavrentieva et al. [27], Kim et al. [25], Cakir et al. [22], Seoane et al. [23] and Paratz et al. [24], the standard error is estimated from AUC confidence interval (SE = (UB-LB) / 3.92).

In Bargues et al. [16], log values were transformed and combined in order to obtain the PCT average and standard deviation, and the subgroup values are combined to obtain the pooled standard deviation and the weight average. Lavrentieva et al. [19] combined subgroup values to obtain the pooled standard deviation and the weight average of PCT for non-sepsis groups.

As Barati et al. [15], Bognar et al. [29] and Mokline et al. [21] did not present AUC standard error, the estimates for standard error were computed using the Hanley and McNeil procedure [30]. Paratz et al. [24] reported the PCT discriminative power as not significant with AUC = 0.38 (95% Confidence Interval (95% CI) 0.29 to 0.46). However, if the classifier was negated on every instance, the true positive (TP) classifications become false negative and the false positive become true negative (TN), and we obtain AUC = 0.62 and, for the cut-off chosen by the authors (1.4 ng/mL), the corresponding sensitivity is 80 and the specificity is 36.

In Lavrentieva et al. [27], Kim et al. [25], Cakir et al. [22], Seoane et al. [23] and Paratz et al. [24], the standard error is estimated from AUC confidence interval (SE = (UB-LB) / 3.92).

Table 1 presents the estimate AUC and the corresponding standard error for each study.

| Study            | Cut-off (ng/mL) | Time points | N   | ROC AUC | SE  | 95%CI     | Tp  | Fp  | Fn  | Tn  |
|------------------|----------------|-------------|-----|---------|-----|-----------|-----|-----|-----|-----|
| Sachse, 1999()   | N/A            | N/A         | 19  | N/A     | N/A | N/A       | N/A | N/A | N/A | N/A |
| von Heimburg, 1998 | 3              | 27          | 27  | N/A     | N/A | 2         | 0   | 16  | 9   |
| Neely, 2004      | 5              | 62          | 20  | N/A     | N/A | N/A       | 11  | 12  | 15  | 24  |
| Abdel-Hafez 2007 | N/A            | N/A         | 42  | N/A     | N/A | N/A       | N/A | N/A | N/A | N/A |
| Bargues, 2007    | 0.534          | 359         | 25  | 0.66    | 0.04| 0.59–0.72 | 39  | 29  | 53  | 237 |
| Lavrentieva, 2007| 1.5            | 934         | 43  | 0.98    | 0.03| 0.91–1.04 | 93  | 72  | 21  | 748 |
| Barati, 2008     | 0.5            | 60          | 60  | 0.97    | 0.02| 0.93–1.01 | 30  | 3   | 0   | 27  |
| Bognar, 2010     | 2              | 196         | 28  | 0.77    | 0.03| 0.70–0.83 | 73  | 32  | 11  | 78  |
| Lavrentieva, 2012| 1.5            | 139         | 145 | 0.97    | 0.01| 0.94–0.99 | 64  | 5   | 9   | 67  |
| Kim, 2012        | 2              | 175         | 175 | 0.84    | 0.03| 0.79–0.90 | 72  | 15  | 21  | 67  |
| Cakir Madenci, 2013 | 0.759         | 611         | 37  | 0.85    | 0.02| 0.81–0.88 | 181 | 79  | 59  | 292 |
| Seoane, 2014     | 1.7            | 34          | 34  | 0.55    | 0.11| 0.33–0.77 | 4   | 0   | 12  | 18  |
| Paratz, 2014     | 1.4            | 345         | 54  | 0.62    | 0.04| 0.54–0.70 | 38  | 190 | 10  | 106 |
| Mokline, 2015    | 0.69           | 121         | 121 | 0.93    | 0.03| 0.87–0.98 | 39  | 12  | 5   | 65  |
| **Total (AUC random effects)** | | | | 0.83 | 0.04 | 0.76–0.90 | | | | |
| **Q**            |                |             |     |         |     | 182.0     |     |     |     |     |
| **p-value**      |                |             |     |         |     | <0.001    |     |     |     |     |
| **I²**           |                |             |     |         |     | 95%       |     |     |     |     |

N—total number of individuals; ROC AUC—receiver operating characteristic area under the curve; 95%CI—95% confidence interval; Fn—false negative; Fp—false positive; N/A—not available; Tn—true negative; Tp—true positive.

doi:10.1371/journal.pone.0168475.t001

Meta-analysis

For all effect sizes under analysis, the studies show significant heterogeneity (p<0.01, I²>50%), thus a random-effects model for meta-analysis was used.

AUC plays a central role in evaluating diagnostic ability of tests, in particular of PCT biomarker. Ten studies under analysis present the PCT AUC estimate value and the first four...
studies reported in Table 1 do not present AUC values. Table 1 presents the overall estimated AUC for PCT for sepsis diagnosis, where the pooled estimate is 0.83 (95% CI = 0.76 to 0.90). PCT diagnosis ability is significant (AUC > 0.5) and the effect size is strong.

The publication bias associated with the AUC on diagnostic sepsis effect was analysed by the funnel plot and the Egger test. The result of Egger’s test was significant (p < 0.001), which is manifested in funnel plot asymmetry (Fig 3). It is of note that the studies appearing to have higher effect in the publication bias are those which had lower AUC values.

To find out sources of heterogeneity, a subgroup analysis was done, using the random effect model, according to different criteria used for sepsis determination in the works of the sample, namely clinical evaluation, Baltimore Sepsis Scale, American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) definition and the more recent and specific one from the American Burn Association (ABA) (Table 2). In order to reduce subjectivity using standardized concepts, this analysis included just the works explicitly employing the ACCP/SCCM or the ABA definition. For the former subgroup, the AUC was 0.87 (95% CI = 0.63 to 1.0) and for the later it was 0.87 (95% CI = 0.71 to 0.90).

We also conducted another subgroup analysis, excluding retrospective studies [31,32], achieved an AUC of 0.86 (95% CI = 0.78 to 0.93).

Similarly to the analysis presented by Ren et al. [13], the summary receiver operating characteristic (SROC) for PCT in sepsis diagnosis was obtained including all the studies considered (four additional studies to those included in Ren et al.). Data reported for SROC estimation by these authors have, however, some differences in comparison to the data used in the present work (Table 1). When the study reported the use of several time-points, the total of time-points...
was used as sample size instead of the total number of individuals [16,19,21,22,24,29]. Moreover, as the revision from Bognar et al. [29] was developed including only septic patients, this feature could add some additional bias.

Fig 4 plots the sensitivity vs the false positive rate of all studies (using the values indicated in Table 1), presenting the SROC and achieving an overall AUC of 0.87 (SE = 0.04). The results produced by this method are in accordance with those obtained directly by the DerSimonian-Laird method (Table 1). The pooled sensitivity and specificity are 0.77 (95% CI = 0.72 to 0.80) and 0.65 (95% CI = 0.62 to 0.69), respectively.

PCT mean values for sepsis and non-sepsis groups for eleven individual studies are presented in Table 3. All the studies presenting the values by groups were considered. Due to the

### Table 2. Study characterization by sepsis criteria employed, type of design and population age.

| Study                  | Sepsis Criteria | Design Type | Population Age |
|------------------------|-----------------|-------------|----------------|
| von Heimburg, 1998     | BSS             | Prospective | Adult          |
| Sasche, 1999          | Clinical        | Retrospective | Mixed         |
| Neely, 2004           | Clinical        | Prospective | Paediatric     |
| Abdel-Hafez, 2007     | Clinical        | Prospective | Paediatric     |
| Bargues, 2007         | ACCP/SCCM       | Prospective | Adult          |
| Lavrentieva, 2007     | ACCP/SCCM       | Prospective | Adult          |
| Barati, 2008          | ACCP/SCCM       | Prospective | Adult          |
| Bognar, 2010          | ABA             | Prospective | Adult          |
| Lavrentieva, 2012     | ABA             | Prospective | Adult          |
| Kim, 2012             | Clinical        | Prospective | Adult          |
| Cakir Madenci, 2013   | ABA             | Prospective | Adult          |
| Seoane, 2014          | ACCP/SCCM       | Retrospective | Adult         |
| Paratz, 2014          | ABA             | Prospective | Adult          |
| Mokline, 2015         | ACCP/SCCM       | Prospective | Adult          |

doi:10.1371/journal.pone.0168475.t002
significant heterogeneity, the overall mean estimate was obtained assuming the random effects model: 46.8 ng/mL (95%CI = 2.5 to 91.1) for sepsis group and 0.9 ng/mL (95%CI = 0.1 to 1.6) for non-sepsis group. This analysis is useful to evaluate the strength of the PCT concentration for each group, and a statistically significant mean difference was observed between sepsis and non-sepsis groups.

In the sepsis group, there are three studies with very high PCT concentration (von Heimburg et al. [17], Bargues et al. [16], Abdel-Hafez et al. [26]) (>45 ng/mL); excluding these studies, an overall PCT mean value of 6.4 ng/mL (95%CI = 3.8 to 9.0) was obtained for the sepsis group and of 0.6 ng/mL (95%CI 0.2 to 0.9) for the non-sepsis group. The mean results are robust after the exclusion of these three studies, which perhaps shall be considered as outliers related to different dosing methodology.

Fig 5 shows the mean difference effect sizes (sepsis and non-sepsis group on PCT concentration) for the eleven studies. Two of these studies (Abdel-Hafez et al. [26], Bargues et al. [16]) reported a much higher difference between groups than the difference observed in the other studies. Due to this clear heterogeneity, a subgroup analysis was performed. Inside both subgroups, the heterogeneity is also significant (p<0.001, Cochrane Q test), justifying
therefore the use of random effects models. The overall sepsis effect is significant (95%CI = 1.1 to 3.2 with overall estimate of 2.1 ng/mL). Including only the low difference group, the overall effect remains significant, but the effect strength is lower (0.9 ng/mL with 95%CI = 0.2 to 1.5), as expected.

Sensitivity analysis by excluding one study at each turn and pooling results from the remainder further confirmed the robustness of the findings, confirming the significance of the sepsis effect on PCT concentration (Table 4).

Discussion

Burns represent a public health problem and are an important cause of mortality and morbidity around the World. According to the World Health Organization (WHO), it is estimated that 265,000 deaths occur every year from fire-related burn injuries. Most of these injuries occur in low- and middle-income countries and almost half of these cases are registered in the South-East Asia Region. Moreover, burns are one of the major causes of disability-adjusted life years (DALYs) lost in these countries. It was estimated in 2004 that nearly 11 million people worldwide were burned severely enough to require medical support. Burns also significantly impact the healthcare-related costs, in particular concerning prolonged hospitalization periods, burn management, and care for disfigurement and emotional trauma [33].
Severe burn injuries that affect all body systems and their regulatory pathways may be considered as a paradigm of polytrauma. Tissue injury, coupled with the release of multiple local and systemic mediators of inflammation, leads to an increase in vascular permeability,
resulting in marked hydroelectrolytic and cardiovascular alterations [34]. These alterations rapidly evolve to a state of hypovolemic shock, with loss of water, proteins and electrolytes, which is usually fatal if not adequately treated. In the past, shock was indeed the first cause of death in these patients. However, the great advances observed in intensive care have reversed this situation and today this initial acute phase of hypovolemia is overcome with success in the majority of the cases [35]. Nowadays, sepsis has become the major cause of death in burn patients, occurring generally in a late post-traumatic period [35,36].

Considering the patients with suspected infection, septic patients have obviously the worst outcomes [37]. These outcomes may be highly improved, if the appropriate antibiotics are administered early and timely [38]. The use of reliable biomarkers that early identify a septic process may have a great importance to help the physicians to select patients for prompt

| Excluded study            | Pooled d | 95%CI          |
|---------------------------|----------|---------------|
| Sachse, 1999              | 2.317    | 1.170–3.464   |
| von Heimburg, 1998        | 2.290    | 1.139–3.442   |
| Neely, 2004               | 2.365    | 1.190–3.539   |
| Abdel-Hafez 2007          | 1.520    | 0.480–2.559   |
| Bargues, 2007             | 1.182    | 0.447–1.917   |
| Lavrentieva, 2007         | 2.279    | 0.992–3.566   |
| Barati, 2008              | 2.237    | 1.067–3.406   |
| Lavrentieva, 2012         | 2.404    | 1.183–3.624   |
| Cakir Madenci, 2013       | 2.467    | 1.204–3.730   |
| Seoane, 2014              | 2.309    | 1.150–3.468   |
| Mokline, 2015             | 2.255    | 1.057–3.453   |

95%CI–95% confidence interval.

doi:10.1371/journal.pone.0168475.t004

Fig 6. Funnel plot of the difference of procalcitonin (PCT) levels between sepsis and non-sepsis groups (Cohen’s d effect sizes).

doi:10.1371/journal.pone.0168475.g006
antibiotic therapy, particularly when clinical signs are absent or unclear. On the other hand, if the biomarker levels are under the cut-off values defined for septic processes, this information may suggest that an inflammatory non-infectious process is occurring. So, these tests are also useful to avoid unnecessary antibiotic therapy, which may result in toxicity and development of antimicrobial resistance.

PCT is a 116-aminoacid prohormone of calcitonin, which is mainly produced by the C-cells of thyroid gland and participates in calcium metabolism [39]. PCT is also synthesised in other tissues, including liver, kidney, lung and adipose tissue, in response to endotoxins, cytokines and other mediators released during the infection period [40]. PCT blood levels are barely detectable in healthy individuals. However, in the presence of systemic bacterial infection or, in a lower scale, fungal infection, its levels suddenly undergo a dramatic increase, following the infection course and then quickly subside after the control of the septic process. There is strong clinical evidence that PCT allows differentiation between non-infectious systemic inflammatory response and microbiological infection by bacteria or fungi and several studies confirm its utility as a reliable means to guide antibiotic use in community-acquired pneumonia and sepsis in intensive care patients [11,12,41–46]. Some studies also suggest its usefulness in the diagnosis and prognosis of sepsis in burn patients [17–19,27,47] [S3 File], though some controversy still persists [16,28,48]. PCT is currently one of the most investigated biomarkers and has already been integrated in treatment algorithms for patients with lower respiratory airways infections [12] and for ICU patients [28].

The main finding of this meta-analysis is that most of the included studies indicate that PCT can be a simple and very useful biomarker for the early identification of sepsis in burn patients, when used in combination with relevant clinical examination and other biomarkers available (e.g. leukocytosis, C-reactive protein, MR-pro-adrenomedullin) [18,49–52]. In fact, the pooled information resulting from this work suggests the feasibility of PCT quantification in these patients, showing that an average cut-off of 1.5 ng/mL is a strong indicator for sepsis suspicion and therefore for the initiation of antibiotherapy.

In addition, this work demonstrated that overall pooled area under the SROC curve was 0.87, with a sensitivity of 0.77 and a specificity of 0.65. The area under the SROC curve and the sensitivity are in agreement with the results published by Ren et al. [13], which reported that the area under the SROC curve was 0.92, with a sensitivity of 0.74. On the other hand, the specificity reported in this work was lower (0.65 vs 0.88) and the publication bias was significant. Thus, the inclusion of four additional studies in this meta-analysis, including two pediatric studies, contribute to support and strengthen the evidence supporting the interest of PCT levels as a biomarker for the early diagnosis of sepsis in burn patients. The sensitivity analysis, performed by excluding one study at each turn, also confirmed the sepsis effect on PCT concentration in burn patients. Nevertheless, the inclusion of these pediatric studies may explain the lower specificity and the higher heterogeneity reported in our work, as a population with different physiologic characteristics was considered in the analysis.

This work also included a sub-group analysis, comparing sepsis and non-sepsis groups of the studies included. This analysis revealed that sepsis group showed a statistical significant increase in the PCT mean values, in comparison with non-sepsis group. It also indicated that both groups were highly heterogeneous, though this parameter was higher in the sepsis group. Moreover, no significant publication bias was registered between sepsis and non-sepsis groups. The increase of PCT levels in patients diagnosed with sepsis corroborates the potential usefulness of this prohormone in burn patients with sepsis.

However, some studies reported that PCT levels can temporarily increase in some patients postoperatively, even in the absence of infection [41]. This increase is minor and rapidly subsides, but it must obviously be taken into account. In addition, some previous studies did not
confirm that PCT levels may be helpful for the diagnosis of sepsis in burn patients [23,24,48], which may result from several factors, such as a small sample size, heterogeneity among patients included in the analysis, different criteria for sepsis diagnosis and different timings of sampling [25].

This work has some limitations that must be considered when interpreting the results. Only 12 studies were available for meta-analysis and the number of patients included was in general small and heterogeneous between the different studies. The cut-offs values, which ranged from 0.5 to 5 ng/mL, and the methods used to quantify the PCT concentration also diverged in these studies. The high heterogeneity of the studies is also a factor that may rise questions about the utility of this biomarker. The inclusion of two pediatric studies, as referred, may had a significant impact in this parameter. Another limitation relies on the origin of the data included in the analysis. In fact, only published studies written in English were considered, which may imply the exclusion of significant and important data obtained in unpublished studies and studies written in other languages.

Based on these studies, in the authors’ opinion, PCT levels should be determined daily in burn patients at high risk of infection (large total body surface area [TBSA] burns, mechanical ventilation, comorbidities, etc.), and at least twice a week for the rest of the burn patients. However, further studies with significant number of patients and planned to reduce the variability of cut-off values, number of timepoints and methods to quantify PCT levels should be conducted, to better evaluate the interest of PCT as a biomarker for early diagnosis of sepsis in burn patients. Studies combining the determination of PCT levels and the evaluation of other potential biomarkers or other clinical evidence should also be done, as generally the single determination of one biomarker is not sufficient to predict or early diagnose the septic process.

**Conclusion**

This meta-analysis showed PCT may be considered as a biomarker with a strong diagnostic ability to discriminate between the septic and the non-septic burn patients. The overall sepsis effect is significant and the overall association between PCT levels and the occurrence of mortality is also significant. This work clearly encourages the serial and frequent measurement of PCT levels in clinical practice for the management of burn patients, in order to timely identify the susceptibility to sepsis and to initiate the antimicrobial therapy, improving the patients’ outcomes.

**Supporting Information**

S1 File. This is the document in Annex 1.
(DOCX)

S2 File. This is the file of Systematic Revision–H. Rao.
(PDF)

S3 File. This is the file of Systematic Revision–E. Mann.
(PDF)

S4 File. This is the file of PRISMA 2009 checklist—The Use of Procalcitonin (PCT) for Diagnosis of Sepsis in Burn Patients.
(DOC)

**Acknowledgments**

The authors want to acknowledge CIDMA (Center for Research and Development in Mathematics and Applications) and iBiMED (Institute for Biomedicine), from the University of
Aveiro, Portugal, for the logistic support and to acknowledge Mariana Costa, PharmD, for her contributions related to the revision of the manuscript.

Author Contributions

Conceptualization: LC JAP.

Formal analysis: VA.

Funding acquisition: LC.

Investigation: LC VA.

Methodology: LC VA.

Project administration: LC LA.

Resources: LC VA.

Software: LC VA LA.

Supervision: JAP.

Validation: LA.

Visualization: LC LA.

Writing – review & editing: LC LA JAP.

References

1. Shelby J, Merrell SW. In vivo monitoring of postburn immune response. J Trauma. 1987; 27(2):213–6. PMID: 3820354

2. Appelgren P, Björnhagen V, Bragderyd K, Jonsson CE, Ransjö U. A prospective study of infections in burn patients. Burns. 2002; 28(1):39–46. PMID: 11834328

3. Englert NC, Ross C. The Older Adult Experiencing Sepsis. Crit Care Nurs Q. 2015; 38(2):175–81. doi: 10.1097/CNQ.0000000000000058 PMID: 25741958

4. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. In: Chest. 1992. p. 1644–55.

5. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31:1250–6. doi: 10.1097/01.CCM.0000050454.01978.3B PMID: 12682500

6. Greenhalgh DG, Saffle JR, Holmes JH, Gamelli RL, Palmieri TL, Horton JW, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007; 28(6):776–80. doi: 10.1097/BCR.0b013e3181599bc9 PMID: 17925660

7. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004; 39 (2):206–17. doi: 10.1086/421987 PMID: 15307030

8. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34:1589–96. doi: 10.1097/01.CCM.0000217961.75225.E9 PMID: 16625125

9. Kollef MHH, Fraser VJJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001; 134(4):298. PMID: 11182841

10. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret G-Y. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006; 34(7):1996–2003. doi: 10.1097/01.CCM.0000226413.54364.36 PMID: 16715031

11. Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol. 2011; 135(2):182–9. doi: 10.1309/AJCP1MFYINQLECV2 PMID: 21228358
12. Schuetz P, Raad I, Amin DN. Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. Curr Opin Crit Care. 2013; 19(5):453–60. doi: 10.1097/MCC.0b013e328363bd38 PMID: 23817026

13. Ren H, Li Y, Han C, Hu H. Serum procalcitonin as a diagnostic biomarker for sepsis in burned patients: A meta-analysis. Burns. 2015; 41(3):502–9. doi: 10.1016/j.burns.2014.08.019 PMID: 25648378

14. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. MetaDiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006; 6:31. doi: 10.1186/1471-2288-6-31 PMID: 16836745

15. Barati M, Alinejad F, Bahar MA, Tabrisi MS, Shamshiri AR, Bodouhi N ol lahe, et al. Comparison of WBC, ESR, CRP and PCT serum levels in septic and non-septic burn cases. Burns. 2008; 34(6):770–4. doi: 10.1016/j.burns.2008.01.014 PMID: 18513877

16. Bargues L, Chance relle Y, Catineau J, Jault P, Carsin H. Evaluation of serum procalcitonin concentration in the ICU following severe burn. Burns. 2007; 33(7):860–4. doi: 10.1016/j.burns.2006.10.401 PMID: 17215085

17. Von Heimburg D, Steighorst W, Khorram-S efat R, Pallua N. Procalcitonin—a sepsis parameter in severe burn injuries. Burns. 1998; 24(8):745–50. PMID: 9915676

18. Sachse C, Machens HG, Felmerer G, Berger A, Henkel E. Procalcitonin as a marker for the early diagnosis of severe infection after thermal injury. Journal of Burn Care and Rehabilitation. 1999. p. 354–60. PMID: 10501320

19. Lavrentieva A, Kontakiotis T, Lazaridis L, Tsotsolis N, Koumis J, Kyriazis G, et al. Inflammatory markers in patients with severe burn injury. What is the best indicator of sepsis? Burns. 2007; 33(2):189–94. doi: 10.1016/j.burns.2006.07.001 PMID: 17215085

20. Neely AN, Fowler L a, Kagan RJ, Warden GD. Procalcitonin in pediatric burn patients: an early indicator of sepsis? J Burn Care Rehabil. 2004; 25(1):76–80. doi: 10.1097/01.BCR.0000105095.94766.89 PMID: 14726743

21. Mokline A, Garsallah L, Rahmani I, Jerbi K., oueslati H., Tlaili S., Hammoud R., Gasri B. M A. Procalcitonin: A diagnostic and prognostic biomarker of sepsis in burned patients. 2015; XXVIII(June):116–20.

22. Cakir Madenci Ó, Yakupoglu S BN, Yu ¨ cel N, Akbaba D OKD. Evaluation of soluble CD14 subtype (pre-sepsin) in burn sepsis. Burns. 2014; 40(4):664–9. doi: 10.1016/j.burns.2013.08.024 PMID: 24074718

23. Seoane L, Pértega S, Galeiras R, Astola I, Bouza T. Procalcitonin in the burn unit and the diagnosis of infection. Burns. 2014; 40(2):223–9. doi: 10.1016/j.burns.2013.11.018 PMID: 24439927

24. Paratz JD, Lipman J, Boots RJ, Muller MJ, Paterson DL. A New Marker of Sepsis Post Burn Injury? Crit Care Med. 2014;(3):2029–36.

25. Kim HS, Yang HT, Hur J, Chun W, Ju YS, Shin SH, et al. Procalcitonin levels within 48 hours after burn injury as a prognostic factor. Ann Clin Lab Sci. 2012; 42(1):57–64. PMID: 22371911

26. Abdel-Haf ez NM, Saleh Hassan Y, El-Metwal ly TH. A study on biomarkers, cytokines, and growth factors in children with burn injuries. Ann Burns Fire Disasters. 2007; 20(2):89–100. PMID: 21991076

27. avrentieva A, Papadopoulou S, Kioumis J, Kaimakamis E, Bitzani M. PCT as a diagnostic and prognostic tool in burn patients. Whether time course has a role in monitoring sepsis treatment. Burns. 2012; 38 (3):356–63. doi: 10.1016/j.burns.2011.08.021 PMID: 22037153

28. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial*. Crit Care Med. 2011; 39(9):2048–58. doi: 10.1097/CCM.0b013e31821e8791 PMID: 21572328

29. Bognár Z, Foldi V, Rezman B, Bogár L, Csontos C. Extravascular lung water index as a sign of developing sepsis in burns. Burns. 2010; 36(8):1263–70. doi: 10.1016/j.burns.2010.04.006 PMID: 20547005

30. Hanley J a, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143(1):29–36. doi: 10.1148/radiology.143.1.7063747 PMID: 7063747

31. Bochud P-Y, Bonten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med. 2004; 32(11 Suppl):S495–512.

32. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009; 302(10):1059–66. doi: 10.1001/jama.2009.1297 PMID: 19738090

33. World Health Organization. WHO | Burn Fact sheet No 365 Updat April 2014.

34. Kramer G. Pathophysiology of burn shock and burn oedema. In: In Total Burn Care (Herndon DN, 4th ed). 2012. p. 103–13.
35. Pereira CT, Barrow RE, Sterns AM, Hawkins HK, Kimbrough CW, Jeschke MG, et al. Age-Dependent Differences in Survival after Severe Burns: A Unicentric Review of 1,674 Patients and 179 Autopsies over 15 Years. J Am Coll Surg. 2016; 202(3):536–48.

36. Krishnan P, Frew Q, Green A, Martin R, Dzwulski P. Cause of death and correlation with autopsy findings in burns patients. Burns. 2013; 39(4):583–8 doi: 10.1016/j.burns.2012.09.017 PMID: 23137628

37. Chipp E, Milner CS, Blackburn A V. Sepsis in burns: a review of current practice and future therapies. Ann Plast Surg. 2010; 65(2):228–36. doi: 10.1097/SAP.0b013e3181c9c35c PMID: 20606586

38. Bates DW, Prouss KE, Lee TH. How bad are bacteremia and sepsis? Outcomes in a cohort with suspected bacteremia. Arch Intern Med. 1995; 155(6):593–8. PMID: 7887754

39. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993; 341(8844):515–8. PMID: 8094770

40. Mehaneic S, Balic R. The importance of serum procalcitonin in diagnosis and treatment of serious bacterial infections and sepsis. Mater Sociomed. 2013; 25(4):277–81. doi: 10.5455/msm.2013.25.277-281 PMID: 24511227

41. Quenot J-P, Luyt C-E, Roche N, Chalumeau M, Charles P-E, Claessens Y-E, et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy. Ann Intensive Care. 2013; 3:21. doi: 10.1186/2110-5820-3-21 PMID: 23830525

42. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2010; 38(11):2229–41. doi: 10.1097/CCM.0b013e3181f17bf9 PMID: 20729729

43. Boudadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwabel C, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010; 375(9713):463–4. doi: 10.1016/S0140-6736(09)61879-1 PMID: 20097417

44. Schuetz P, Chiappa Y, Briel M, Greenwald JL. Procalcitonin Algorithms for Antibiotic Therapy Decisions. Arch Intern Med. 2011; 171(15):1322–31. doi: 10.1001/archinternmed.2011.318 PMID: 21824946

45. Matthaiou DK, Ntani G, Kontogiorgi M, Poulaou G, Armaganidis A, Dimopoulos G. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Medicine; 2012; 38(6):940–9. doi: 10.1007/s00134-012-2563-7 PMID: 22538461

46. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tammi M, Boudadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evidence-Based Child Heal. 2013; 8(4):1297–371.

47. Mann EA, Wood GL, Wade CE. Use of procalcitonin for the detection of sepsis in the critically ill burn patient: A systematic review of the literature. Burns. 2011. p. 549–58. doi: 10.1016/j.burns.2010.04.013 PMID: 20537467

48. Carsin H, Assicot M, Feger F, Roy O, Pennacino I, Le Bever H, et al. Evolution and significance of circulating procalcitonin levels compared with IL-6, TNFα and endotoxin levels early after thermal injury. Burns. 1997; 23(3):218–24. PMID: 9232281

49. Cho SY, Choi JH. Biomarkers of Sepsis. Infection and Chemotherapy. 2014. p. 1–12. doi: 10.3947/ic.2014.46.1.1 PMID: 24693464

50. Angeletti S, Battistoni F, Fioravanti M, Bernardini S, Dicuonzio G. Procalcitonin and mid-regional pro-adrenomedullin test combination in sepsis diagnosis. Clin Chem Lab Med. 2013; 51(5):1059–67. doi: 10.1515/cclm-2012-0595 PMID: 23072859

51. Angeletti S, Spoto S, Fogolari M, Cortigiani M, Fioravanti M, De Florio L, et al. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections. APMIS. 2015; 123(9):740–8. doi: 10.1111/apm.12406 PMID: 26058482

52. Angeletti S, Dicuonzio G, Fioravanti M, De Cesaris M, Fogolari M, Lo Presti A, et al. Procalcitonin, MR-Proadrenomedullin, and cytokines measurement in sepsis diagnosis: Advantages from test combination. Dis Markers. 2015; 2015.